• Anna Waszczuk-Gajda, Sylwia Szafraniec-Buryło, Leszek Kraj, Kamila Skwierawska, Kinga Aleksandrowicz, Grzegorz Władysław Basak, Melania Brzozowska, Waldemar Wierzba, Wiesław Wiktor Jędrzejczak, and Andrzej Śliwczyński.
• Department of Haematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland.
• Arch Med Sci. 2023 Jan 1; 19 (3): 645650645-650.

IntroductionMultiple myeloma is the third most common blood cancer in Europe and accounts for approx. 10-15% of these cancers. The objective of this study was to determine the incidence, prevalence, mortality and survival in multiple myeloma (ICD code: C90.0) patients in Poland in the years 2008-2017.Material And MethodsThe analysis used the data on healthcare services provided to patients with multiple myeloma defined with the ICD-10 (International Statistical Classification of Diseases and Related Health Problems) code C90.0 and reported by healthcare entities to the National Health Fund (NFZ).ResultsIn 2009, the C90.0 incidence per 100,000 inhabitants was 6.4, while in 2017 it was 8.3. The prevalence in the same period increased by 76%, from 13.6/100,000 to 23.9/100,000. The mortality to prevalence ratio gradually decreased from 78% in 2008 to 22.8% in 2017. The 1-year, 3-year and 5-year survival rates in patients with this diagnosis made in the years 2009 and 2013 were 70.5%, 51.5% and 40.2% versus 78.4%, 60.3% and 48.3%, respectively.ConclusionsThe incidence and prevalence of multiple myeloma and survival rates in Poland were continuously increasing in the studied period. These trends may result from the aging of Polish society, better recognisability of multiple myeloma and/or improved access to increasingly more effective therapies in Poland. The impact of these factors on the epidemiology of multiple myeloma requires further studies.Copyright: © 2020 Termedia & Banach.

6 keywords...

hide…